CRISPR

The Readout Damian Garde

STAT Plus: What if there’s no market for a CRISPR cure?

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Listen: Merger Mondays, Ozempic panic, & CRISPR’d pigs

Biotech Megan Molteni

STAT Plus: In major test for eGenesis, gene-edited pig kidneys kept monkeys alive for more than two years

In the Lab Jason Mast

STAT Plus: Carl June unveils a plan for a ‘universal CAR-T’

Biotech Megan Molteni

STAT Plus: Intellia plays down concerns about accidental germline transmission in CRISPR trial

In the Lab Angus Chen

STAT Plus: A yogurt drink instead of a colonoscopy? Study uses engineered bacteria to detect cancer

Biotech Jason Mast

STAT Plus: Sanofi licenses CRISPR enzyme in bid to develop safer, simpler sickle cell cure

In the Lab Andrew Joseph

Researchers turn to CRISPR to unlock one of the trickiest diseases to treat: Alzheimer’s

Biotech Andrew Joseph

STAT Plus: Trailing other sickle cell drug makers, Editas still sees opportunity for its CRISPR therapy

Biotech Andrew Joseph

STAT Plus: Updated data show long-term benefits of CRISPR treatment for sickle cell, beta thalassemia

Biotech Megan Molteni

STAT Plus: In its first tough test, CRISPR epigenome editing cuts cholesterol levels in monkeys

Biotech Jason Mast

STAT Plus: Gene therapy death not caused by CRISPR, investigators confirm

Biotech Jason Mast

STAT Plus: Doudna talks cost, access issues looming over first CRISPR therapy

Exclusive Jason Mast

STAT Plus: Early findings in gene therapy death suggest CRISPR was not the cause

In the Lab Jason Mast

STAT Plus: Researchers devise new strategies to overcome a key CRISPR flaw

In the Lab Megan Molteni

Setting aside the thorniest issues around CRISPR babies, scientists say embryo-editing research should proceed

In the Lab Megan Molteni

STAT Plus: Mice with two fathers and base-edited baby monkeys highlight potential — and limitations — of hereditable gene editing

In the Lab Megan Molteni

With CRISPR cures on horizon, sickle cell patients ask hard questions about who can access them

In the Lab Megan Molteni

STAT Plus: At genome-editing summit, experts worry that rule changes on embryo research in China fall short

In the Lab Megan Molteni

STAT Plus: Ahead of genome summit in London, questions linger about CRISPR baby scandal

The Readout LOUD Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: The next CRISPR fight, cheaper insulin, & an FDA shuffle

Special Report Jason Mast, Allison DeAngelis, and Megan Molteni

STAT Plus: CRISPR patent fight redux? A new battle is brewing among biotechs over next-gen gene-editing tools

Biotech Ryan Cross — The Boston Globe

STAT Plus: Moderna expands CRISPR gene editing research with ElevateBio partnership

In the Lab Kanis Leung and Emily Wang Fujiyama — Associated Press

Hong Kong pulls visa for ‘CRISPR babies’ scientist He Jiankui

Biotech Allison DeAngelis

STAT Plus: CRISPR pioneer Feng Zhang launches new genetic delivery startup with $193 million

Biotech Megan Molteni

STAT Plus: ‘Make People Better’: The CRISPR babies story you probably don’t know, and how it was filmed in real-time

In the Lab Megan Molteni

After three years in prison, ‘CRISPR babies’ scientist is attempting a comeback

Biotech Jason Mast

STAT Plus: Editas, facing another setback, halts development on first clinical CRISPR program

Biotech Megan Molteni

STAT Plus: Perfection is too high a bar for CRISPR treatments, says STAT Biomedical Innovation Award winner David Liu